GE 226
Alternative Names: [18F]FBA-ZHER2:2891; [18F]GE-226; Fluorine-18 GE 226; GE-226Latest Information Update: 28 Feb 2024
At a glance
- Originator Affibody; GE Healthcare
- Class Imaging agents; Peptide diagnostics; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported HER2 positive breast cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in HER2-positive-breast-cancer(Diagnosis) in United Kingdom (IV, Injection)
- 11 Jul 2022 18F GE 226 is available for licensing as of 11 Jul 2022. affibody.se/partnering/
- 03 Jun 2022 Adverse events and pharmacokinetics data from a phase I trial in Breast caner presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)